Literature DB >> 9035000

A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome.

A Okifuji1, D C Turk, J D Sinclair, T W Starz, D A Marcus.   

Abstract

OBJECTIVE: To (a) develop a standardized tender point examination protocol [Manual Tender Point Survey (MTPS)] as a diagnostic procedure to evaluate the tender point (TP) criterion for fibromyalgia syndrome (FM) and (b) determine a threshold point for positive TP.
METHODS: A standardized MTPS consisted of standardized components including (a) location of the survey sites, (b) patient and examiner positioning, (c) order of examination, (d) pressure application technique, and (e) pain severity rating scores [0 (no pain) - 10 (worst pain)]. Seventy patients with FM and 70 with chronic headache were examined using the MTPS protocol.
RESULTS: A pain severity score of 2 (i.e., 0-1 = negative) was found to be an optimal threshold point for identifying positive TP, with sensitivity of 88.57% and specificity of 71.43%. These results are comparable to the sensitivity and specificity of the 1990 multicenter study.
CONCLUSION: The MTPS provides a step-by-step, standardized TP examination protocol, which is sensitive and specific in discriminating patients with FM from patients with chronic headache.

Entities:  

Mesh:

Year:  1997        PMID: 9035000

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  49 in total

1.  Positive affect as a source of resilience for women in chronic pain.

Authors:  Alex J Zautra; Lisa M Johnson; Mary C Davis
Journal:  J Consult Clin Psychol       Date:  2005-04

2.  Fibromyalgia: revisiting the literature.

Authors:  Diane Forbes; Andrew Chalmers
Journal:  J Can Chiropr Assoc       Date:  2004-06

3.  Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.

Authors:  Kathleen C Light; Edith E Bragdon; Karen M Grewen; Kimberly A Brownley; Susan S Girdler; William Maixner
Journal:  J Pain       Date:  2009-05       Impact factor: 5.820

4.  Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial.

Authors:  Gudrun Lange; Malvin N Janal; Allen Maniker; Jennifer Fitzgibbons; Malusha Fobler; Dane Cook; Benjamin H Natelson
Journal:  Pain Med       Date:  2011-08-03       Impact factor: 3.750

5.  Transcranial magnetic stimulation in the treatment of chronic widespread pain: a randomized controlled study.

Authors:  David H Avery; Paul Zarkowski; Daniel Krashin; Wang-Ku Rho; Chandra Wajdik; Jutta M Joesch; David R Haynor; Dedra Buchwald; Peter Roy-Byrne
Journal:  J ECT       Date:  2015-03       Impact factor: 3.635

6.  Treatment-related changes in brain activation in patients with fibromyalgia syndrome.

Authors:  Martin Diers; Pinar Yilmaz; Mariela Rance; Kati Thieme; Richard H Gracely; Claudia Rolko; Marcus T Schley; Ulrike Kiessling; Haili Wang; Herta Flor
Journal:  Exp Brain Res       Date:  2012-03-17       Impact factor: 1.972

7.  Sequential analyses of daily symptoms in women with fibromyalgia syndrome.

Authors:  Akiko Okifuji; David H Bradshaw; Gary W Donaldson; Dennis C Turk
Journal:  J Pain       Date:  2010-07-01       Impact factor: 5.820

8.  Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

Authors:  Akiko Okifuji; David H Bradshaw; Chrisana Olson
Journal:  Clin Rheumatol       Date:  2009-01-27       Impact factor: 2.980

9.  [How reliable are statements on extensive noninflammatory pain? Comparison of patients with fibromyalgia, backache, and other local pain].

Authors:  R Dohrenbusch; L Sampaio-Doherty; E Genth
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

10.  Prevalence of fibromyalgia in a low socioeconomic status population.

Authors:  Ana Assumpção; Alane B Cavalcante; Cristina E Capela; Juliana F Sauer; Suellen D Chalot; Carlos A B Pereira; Amélia P Marques
Journal:  BMC Musculoskelet Disord       Date:  2009-06-08       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.